Intellia Therapeutics (NTLA) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.91

Estimate

-$0.79

Surprise

-15.8%

Revenue (period 2026-09-30)

$7.2M

Score today

3.5/10

Revenue source: xbrl.

Intellia Therapeutics (NTLA) reported a wider loss than forecast — adjusted EPS of -$0.91 against the -$0.79 estimate (a 15.8% shortfall).

• Intellia Therapeutics Announces Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-05
• Intellia Therapeutics Q3 EPS $(0.91) Misses $(0.80) Estimate, Sales $7.163M Miss $10.461M Estimate — benzinga, 2026-11-05
• Intellia Completed Enrollment In MAGNITUDE-2 Phase 3 Trial Of Nex-z In ATTRv-PN; Cash $614.8M, Expects Runway At Least I — benzinga, 2026-11-05

TrendMatrix currently rates NTLA Sell at 3.5/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -15.8% surprise compares with a +1.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$11.14

Price target

$20.80

Stop

$10.36

Upside to target

+86.6%

Reward-to-risk

5.8:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.56B

P/E (fwd)

-4.3

52-week range

$7.95–$18.48

Off 52-week high

39.7%

RSI (14)

47

Volume vs avg

0.36×

Score today

3.5/10